載入中
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
前收盤價
US$4.84
−US$0.14 · -2.81%
盤中時間採用ET。市場資料可能有所延遲。
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
日內區間
目前US$4.84
52週區間
目前US$4.84
盤中時間採用ET。市場資料可能有所延遲。
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
日內區間
目前US$4.84
52週區間
目前US$4.84
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 5942.5萬 USD | 5694.4萬 USD | 5015.5萬 USD | 5387萬 USD | 4910.9萬 USD |
| 銷貨成本 | 3090萬 USD | 2838.9萬 USD | 2940.1萬 USD | 2953.2萬 USD | 2363.2萬 USD |
| 毛利 | 2852.5萬 USD | 2855.5萬 USD | 2075.4萬 USD | 2433.8萬 USD | 2547.7萬 USD |
| 研究與開發 | 908.4萬 USD | 682.5萬 USD | 954.4萬 USD | 1154.5萬 USD | 937.4萬 USD |
| 銷售、一般及管理費用 | 2047萬 USD | 1688.4萬 USD | 1813.1萬 USD | 1724.2萬 USD | 1549.6萬 USD |
| 營業費用 | 2966.5萬 USD | 2370.9萬 USD | 2767.5萬 USD | 2878.7萬 USD | 2487萬 USD |
| 折舊和攤銷 | 137.7萬 USD | 164萬 USD | 186.7萬 USD | 224.6萬 USD | 162.7萬 USD |
| 營業利益 | −114萬 USD | 484.6萬 USD | −692.1萬 USD | −444.9萬 USD | 60.7萬 USD |
| 淨利 | −117.5萬 USD | 470.1萬 USD | −727.6萬 USD | −533.5萬 USD | 54.8萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$12.00
上漲空間 147.93%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2015年8月12日 | 1:12 | — | — |
已生效 2015年8月12日
1:12
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
